Zydus Cadila gets USFDA okay for Fingolimod Capsules, Verapamil Hydrochloride Injection

Published On 2020-10-17 05:46 GMT   |   Update On 2023-10-09 09:43 GMT
Advertisement

Ahmedabad: Drugmaker, Zydus Cadila, has recently announced that the company has received final approval from the USFDA to market Fingolimod Capsules, 0.5 mg (US RLD: Gilenya® Capsules).

Fingolimod is an immunomodulating drug. It is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS).

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The Company has also received the final approval from the USFDA to market Verapamil Hydrochloride Injection USP, 5 mg/2 mL (2.5 mg/mL) and 10 mg/4 mL (2.5 mg/mL), Single-Dose Vials(US RLD: Isoptin Injection).

The injections will be manufactured at the company's manufacturing facility at Jarod, near Vadodara (formerly known as Liva Pharmaceuticals).

Verapamil injection is used to rapidly or temporarily restore normal heartbeats in people with certain heart rhythm disorders.

The group now has 305 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Read also: Zydus Cadila unveils pressurized Metered Dose Inhaler for COPD patients in India

Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India.

The company discovers, develops, manufactures, and markets a broad range of healthcare therapies.





Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News